LUNDORFF, MD, L.; SJØGREN, DMSCI, MD, P.; HANSEN, MD, O. B.; JONSSON, MD, T.; NIELSEN, P. R.; CHRISTRUP, PHD, MSC(PHARM), L. Switching from high doses of pure µ-opioid agonists to transdermal buprenorphine in patients with cancer: A feasibility study. Journal of Opioid Management, [S. l.], v. 9, n. 4, p. 255–262, 2013. DOI: 10.5055/jom.2013.0166. Disponível em: https://wmpllc.org/ojs/index.php/jom/article/view/568. Acesso em: 30 apr. 2024.